Latest Posts:

Sorry, no posts matched your criteria.

Follow Us:

Back To Top

Associate: LEADING NEW OPPORTUNITY DISCOVERY IN THERAPEUTICS

Building ventures that design more effective personalised therapies significantly extending healthy lifespan.

Full time on a temporary contract fixed for 6 months, starting asap, remotely or London-based

About DSV-Pharma

DSV builds and coordinates consortia of sponsors, institutes, advisors, labs and investors to create innovative startups with tested team members, technologies, customers and investors.

The current rate of therapeutic failure is unsustainable and unnecessary. The reasons are well understood, including poor models and lack of specificity, but often simply put down to “science is hard” or lost in a whirlwind of hype around AI. In reality, the knowledge and toolsets are available, but the failure rate of therapeutics remains unconscionably high. This is due to entrenched biases at every stage, from publishing papers to clinician marketing. We work to a thesis which addresses these constraints.

You can read more about our Curative therapeutics thesis here.

 

About the role

As an Associate you will work in close partnership with the Associate Director for Pharma and our current or future pharma sector Founders focusing on systemic analysis or “scoping”, as we call it, of opportunity areas (OAs) for new venture development, identifying the sort of technologies and ventures that should exist but don’t.

While your main focus will be on opportunity analysis, you’ll be involved across all core functions of venture development, including recruitment and team building, business development, fundraising and portfolio management to quickly develop a broad understanding of the scope of all activities within the business.

 

Key responsibilities:

● Optimise DSV’s existing opportunity areas (OAs) in the sector supporting the Associate Director with research and analysis for venture development;

● Research and identify potential new OAs for the sector;

● Support team building and recruitment of multidisciplinary founder-type scientists across all live OAs;

● Support any current and/or future Founders on concept and/or commercial development in DSV’s existing areas from idea generation to investment;

● Support fundraising and business development efforts for the sector.

 

About you

Key requirements:

● Deep technical understanding in more than one therapeutic fields and broad knowledge, and interests across areas such as oncology, neurodegeneration, cardiovascular disease etc.

● You’ll likely have done a PhD in any of (or similar): cell and gene therapy, cell engineering, cell and developmental biology, molecular virology, biochemistry and molecular biology etc.

● Demonstrated interest in applied science/translation biology. Interest in early stage commercialisation is a plus, ideally with <2 years experience working in startups / VC and/or Analyst type roles.

● Demonstrated level of achievement, taking own initiative and delivering outcome-oriented projects from start to finish. You make things happen.

Team Pharma

Kerstin: Previously led research commercialisation at the UK Government’s flagship initiative for Cell & Gene Therapy where she worked with every major academic life sciences department in the UK. Also held a major role at LifeArc (formerly MRCT), the charity responsible for supporting breakthrough drugs Keytruda ($40bn+ p.a.), Entyvio, Actemra and Tysabri to market. 

Laura: 15 years of strategic partnership experience at one of the worlds largest funders of research, driven £20m+ R&D funding deals with industry and research funders, extensive track record in licensing and spin out formation. PhD in insulin signalling and research experience in academia and industry.

Anis: Immunology researcher at UCB, New therapeutic concepts (oncology) researcher at Boehringer Ingelheim, QA at Lonza on GMP and FDA readiness, PhD candidate in single-cell RNA seq for breast cancer at Oxford.

Kerstin: Previously led research commercialisation at the UK Government’s flagship initiative for Cell & Gene Therapy where she worked with every major academic life sciences department in the UK. Also held a major role at LifeArc (formerly MRCT), the charity responsible for supporting breakthrough drugs Keytruda ($40bn+ p.a.), Entyvio, Actemra and Tysabri to market. 

Laura: 15 years of strategic partnership experience at one of the worlds largest funders of research, driven £20m+ R&D funding deals with industry and research funders, extensive track record in licensing and spin out formation. PhD in insulin signalling and research experience in academia and industry.

Anis: Immunology researcher at UCB, New therapeutic concepts (oncology) researcher at Boehringer Ingelheim, QA at Lonza on GMP and FDA readiness, PhD candidate in single-cell RNA seq for breast cancer at Oxford.

Jana: PhD Candidate at King’s undertaken in Dr John Maher’s group, generating chimeric antigen receptor (CAR) T cells for the targeting of solid tumours. Previously part of the Investigative Toxicology group at UCB BioPharma developing, validating and implementing novel translational molecular biomarkers.

Jana: PhD Candidate at King’s undertaken in Dr John Maher’s group, generating chimeric antigen receptor (CAR) T cells for the targeting of solid tumours. Previously part of the Investigative Toxicology group at UCB BioPharma developing, validating and implementing novel translational molecular biomarkers.

About DSV

DSV specialises in outcome-centric venture design for science and engineering. We’re optimising global R&D for impact and value creation. We’re working on redesigning industries with a top down vision, venture by venture.

You’ll be part of a small adventurous team though with huge growth ambitions, driven by the desire to make a massive positive impact on the world. We work globally across 24 countries with nearly 400 people including our sector-specific advisors, strategic partners and collaborators.

 

 

Contact

For further info and to discuss the role, please submit an expression of interest.